Overview

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Status:
Completed

Trial end date:
2004-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin, and capecitabine in treating patients who have unresectable locally advanced, metastatic, or recurrent solid tumor.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Collaborator:

National Cancer Institute (NCI)

Treatments:

Capecitabine
Carboplatin
Epirubicin